Science: receptor targeted nanoparticles in the treatment of primary and metastatic breast cancer
-
Last Update: 2020-02-19
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
February 19, 2020 / bioin / -- because many nano carriers and target molecules will be non-specific binding with cell, extracellular and intravascular components, it is quite challenging to develop effective tumor cell targeted nano pharmaceutical preparations Recently, researchers from the University of Maryland School of medicine and other units have developed a therapeutic nanoparticle treatment platform, which can balance the specific binding affinity of cell surface receptors, while maintaining the minimum interaction with blood and tumor tissue components (known as "dart" nanoparticles), so as to improve blood circulation time, biological distribution and tumor Cell specific uptake According to the researchers, in the mouse model of primary three negative breast cancer and brain metastasis of breast cancer, the paclitaxel (PTX) - dart nanoparticles that can be directed to the cell surface receptor fibroblast growth factor-induced 14 (Fn14) are superior to the corresponding PTX nanoparticles without target group and the FDA approved PTX nanoparticles Abraxane These results provide new ideas for the effective development of therapeutic nanoparticles and evidence for the continued development of dart platform for primary and metastatic tumors Reference: Anthony J Kim et al Declared non specific advice, receiver targeted thermal Nanoparticals for primary and metric burst cancer Science advances 15 Jan 2020: Vol 6, No 3, eaax3931 doi: 10.1126/sciadv.aax3931
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
